1. Lonidamine induces apoptosis in drug-resistant cells independently of the p53 gene
- Author
-
Donatella Del Bufalo, Annamaria Biroccio, Ada Sacchi, Silvia Soddu, Carmen D'Angelo, Nina Laudonio, and Gabriella Zupi
- Subjects
Indazoles ,Mutant ,Drug Resistance ,Antineoplastic Agents ,Apoptosis ,Breast Neoplasms ,Endogeny ,Biology ,Cell Line ,chemistry.chemical_compound ,Tumor Cells, Cultured ,medicine ,Humans ,Doxorubicin ,Treatment Failure ,Lonidamine ,General Medicine ,Cell cycle ,Carmustine ,chemistry ,Cell culture ,Cancer research ,DNA fragmentation ,Female ,Tumor Suppressor Protein p53 ,Glioblastoma ,Research Article ,medicine.drug - Abstract
Lonidamine, a dichlorinated derivative of indazole-3-carboxylic acid, was shown to play a significant role in reversing or overcoming multidrug resistance. Here, we show that exposure to 50 microg/ml of lonidamine induces apoptosis in adriamycin and nitrosourea-resistant cells (MCF-7 ADR(r) human breast cancer cell line, and LB9 glioblastoma multiform cell line), as demonstrated by sub-G1 peaks in DNA content histograms, condensation of nuclear chromatin, and internucleosomal DNA fragmentation. Moreover, we find that apoptosis is preceded by accumulation of the cells in the G0/G1 phase of the cell cycle. Interestingly, lonidamine fails to activate the apoptotic program in the corresponding sensitive parental cell lines (ADR-sensitive MCF-7 WT, and nitrosourea-sensitive LI cells) even after long exposure times. The evaluation of bcl-2 protein expression suggests that this different effect of lonidamine treatment in drug-resistant and -sensitive cell lines might not simply be due to dissimilar expression levels of bcl-2 protein. To determine whether the lonidamine-induced apoptosis is mediated by p53 protein, we used cells lacking endogenous p53 and overexpressing either wild-type p53 or dominant-negative p53 mutant. We find that apoptosis by lonidamine is independent of the p53 gene.
- Published
- 1996